Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Accumulated Expenses: 2012-2025

Historic Accumulated Expenses for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to $30.7 million.

  • Enanta Pharmaceuticals' Accumulated Expenses fell 10.89% to $30.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $30.7 million, marking a year-over-year decrease of 10.89%. This contributed to the annual value of $30.7 million for FY2025, which is 10.89% down from last year.
  • Enanta Pharmaceuticals' Accumulated Expenses amounted to $30.7 million in FY2025, which was down 10.89% from $34.5 million recorded in FY2024.
  • Over the past 5 years, Enanta Pharmaceuticals' Accumulated Expenses peaked at $35.1 million during FY2023, and registered a low of $20.9 million during FY2022.
  • For the 3-year period, Enanta Pharmaceuticals' Accumulated Expenses averaged around $33.4 million, with its median value being $34.5 million (2024).
  • Per our database at Business Quant, Enanta Pharmaceuticals' Accumulated Expenses spiked by 67.54% in 2023 and then dropped by 10.89% in 2025.
  • Over the past 5 years, Enanta Pharmaceuticals' Accumulated Expenses (Yearly) stood at $22.4 million in 2021, then fell by 6.66% to $20.9 million in 2022, then spiked by 67.54% to $35.1 million in 2023, then declined by 1.75% to $34.5 million in 2024, then declined by 10.89% to $30.7 million in 2025.